Biocon Biologics Announces New Dermatology Data to Be Presented at EADV Congress 2024

Biocon Biologics Ltd. Netherlands India

Switching between adalimumab and adalimumab-fkjp in Phase 3 study in patients with chronic plaque psoriasis supports interchangeability between adalimumab and adalimumab-fkjpBiosimilarity between Bmab 1200 and reference biologic-Ustekinumab in pivotal Phase 3 trial in patients with moderate to severe chronic plaque psoriasisView original content:https://www.prnewswire.co.uk/news-releases/biocon-biologics-announces-new-dermatology-data-to-be-presented-at-eadv-congress-2024-302258099.html